AIM ImmunoTech Inc.

AIM NYSE CIK: 0000946644

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 2117 SW HIGHWAY 484, OCALA, FL, 32801
Mailing Address 2117 SW HIGHWAY 484, OCALA, FL, 32801
Phone 352-448-7797
Fiscal Year End 1231
EIN 520845822

Financial Overview

FY2025

$8.61M
Total Assets
$15.56M
Total Liabilities

Recent SEC Filings

Form Type Date Filed Document
10-K Annual financial report March 27, 2026 View on SEC
4 Insider stock transaction report March 16, 2026 View on SEC
4 Insider stock transaction report March 16, 2026 View on SEC
4 Insider stock transaction report March 10, 2026 View on SEC
4 Insider stock transaction report March 10, 2026 View on SEC
8-K Current report of material events March 6, 2026 View on SEC
424B4 Prospectus for IPO or offering February 17, 2026 View on SEC
S-1/A IPO registration amendment February 10, 2026 View on SEC
4 Insider stock transaction report February 6, 2026 View on SEC
8-K Current report of material events February 5, 2026 View on SEC

Annual Reports

10-K March 27, 2026
  • Advancing the Phase 2/3 DURAPB clinical trial for pancreatic cancer.
  • Focused development of lead drug candidate Ampligen (rintatolimod).
View Analysis

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.